Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 1/20 | 0.50 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.50 |
| ▸ | ITGAL | P20701 | 1/20 | 0.50 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CRHBP | P24387 | 2/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15982282 | 0.94 | SMN1; SMN2 (0.56) | ITGB2ICAM1ITGALMAP3K14MTNR1A | |
| SCHEMBL15982274 | 0.94 | SMN1; SMN2 (0.56) | ITGB2ICAM1ITGALMAP3K14MTNR1A | |
| SCHEMBL15982298 | 0.94 | SMN1; SMN2 (0.56) | ITGB2ICAM1ITGALMAP3K14MTNR1A | |
| SCHEMBL436487 | 0.91 | MAP3K14 (0.46) | ITGB2ICAM1ITGALMAP3K14MTNR1A | |
| SCHEMBL669020 | 0.84 | MTNR1A (0.42) | ITGB2ICAM1ITGALMAP3K14MTNR1A | |
| SCHEMBL423289 | 0.82 | ABCG2 (0.50) | MAP3K14 | |
| O-Xylene SCHEMBL522767 | 0.78 | ITGB2 (0.74) | ITGB2ICAM1ITGALMAP3K14LMNA | |
| SCHEMBL2306687 | 0.77 | ITGB2 (0.50) | ITGB2ICAM1ITGALMTNR1ALMNA | |
| SCHEMBL3072409 | 0.76 | ITGB2 (0.55) | ITGB2ICAM1ITGALMTNR1ALMNA | |
| SCHEMBL6569085 | 0.75 | MAP3K14 (0.36) | MAP3K14SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 449 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2024130342-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | disclosed |
| EP-4308575-A1 | MACROCYCLES AS CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| US-20230348436-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-11-02 | — | — | US | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4219465-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme Inc (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3498701-B1 | PRMT5 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-1197797-A | New heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | ADIR (FR) | 1998-11-04 | — | — | CN | disclosed |
| EP-0873993-A1 | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-10-28 | — | — | EP | disclosed |
| US-5663189-A | RESPIRATORY, EYES, GASTROINTESTINAL | THE PROCTER & GAMBLE COMPANY (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0496342-B1 | New hydrazine derivative and pesticidal composition comprising said derivative as an effective ingredient | NIPPON KAYAKU KK (JP) | 1996-11-27 | — | — | EP | disclosed |
| EP-0741709-A1 | AROMATIC 2-AMINO-IMIDAZOLE DERIVATIVES AS ALPHA-2A ADRENOCEPTOR AGONISTS | Allergan (US) | 1996-11-13 | — | — | EP | disclosed |
| US-5530021-A | AGRICULTURAL INSECTICIDES | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1996-06-25 | — | — | US | disclosed |
| WO-1995019968-A1 | AROMATIC 2-AMINO-IMIDAZOLE DERIVATIVES AS ALPHA-2A ADRENOCEPTOR AGONISTS | ALLERGAN (US) | 1995-07-27 | — | — | WO | disclosed |
| US-5378726-A | Insecticide, parasiticide | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1995-01-03 | — | — | US | disclosed |
| EP-0496342-A1 | New hydrazine derivative and pesticidal composition comprising said derivative as an effective ingredient | Nippon Kayaku Kabushiki Kaisha (JP) | 1992-07-29 | — | — | EP | disclosed |
| EP-0359290-A1 | Aromatic diols | GLAXO GROUP LIMITED (GB) | 1990-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ITGB2 1499/4885ICAM1 3648/4885ITGAL 2788/4885 |
| US-20230348436-A1 | COMPOUNDS FOR TREATING TUBERCULOSIS | DOT1L, HAT1, UQCRB | ITGB2 2911/4885ICAM1 4696/4885ITGAL 1805/4885 |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | ITGB2 1180/4885ICAM1 4087/4885ITGAL 1944/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ITGB2 4161/4885ICAM1 4769/4885ITGAL 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.